Skip to main content

Table 1 The results of the combined susceptibility test of flavaspidic acid BB and mupirocin

From: Flavaspidic acid BB combined with mupirocin improves its anti-bacterial and anti-biofilm activities against Staphylococcus epidermidis

Strain No

BB (μg/mL)

mupirocin (μg/mL)

FICI

Effects of actions α

MICsingle

MICcombined

MICsingle

MICcombined

SE01

44.67

15.00

20.00

1.56

0.30(± 0.03)

Synergistic effect

SE02

60.00

20.00*

4266.67

453.33**

0.45(± 0.08)

Synergistic effect

SE03

44.89

11.25

0.098

0.015

0.43(± 0.08)

Synergistic effect

SE04

45.91

18.33

5120.00

666.67**

0.36(± 0.08)

Synergistic effect

SE05

48.00

10.00*

5120.00

1280.00**

0.48(± 0.05)

Synergistic effect

SE06

144.00

36.00**

5120.00

768.00**

0.40(± 0.05)

Synergistic effect

SE07

50.00

10.94*

25.00

5.00

0.42(± 0.08)

Synergistic effect

SE08

40.00

4.38*

32.50

6.16

0.36(± 0.03)

Synergistic effect

SE09

25.00

3.75

20.00

4.38

0.41(± 0.10)

Synergistic effect

SE10

41.30

13.75

5120.00

960.00**

0.44(± 0.06)

Synergistic effect

SE11

40.00

12.50

20.00

2.19

0.41(± 0.10)

Synergistic effect

  1. αThe effect of the combined medication is determined by the FICI value (the standard deviations (SD) of the FICI value is shown in parentheses). * denote significant differences between the groups of drug-combination and single drug, as determined by one-way ANOVA (*means P < 0.05, ** means P < 0.01)